[go: up one dir, main page]

WO2004045380A3 - Compositions containing an active fraction isolated from tannins and methods of use - Google Patents

Compositions containing an active fraction isolated from tannins and methods of use Download PDF

Info

Publication number
WO2004045380A3
WO2004045380A3 PCT/US2003/036708 US0336708W WO2004045380A3 WO 2004045380 A3 WO2004045380 A3 WO 2004045380A3 US 0336708 W US0336708 W US 0336708W WO 2004045380 A3 WO2004045380 A3 WO 2004045380A3
Authority
WO
WIPO (PCT)
Prior art keywords
tannins
methods
compositions containing
active fraction
fraction isolated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/036708
Other languages
French (fr)
Other versions
WO2004045380A2 (en
Inventor
Kin-Ping Wong
Ming-Chung Wong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wackvom Ltd
Original Assignee
Wackvom Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wackvom Ltd filed Critical Wackvom Ltd
Priority to AU2003291015A priority Critical patent/AU2003291015A1/en
Publication of WO2004045380A2 publication Critical patent/WO2004045380A2/en
Publication of WO2004045380A3 publication Critical patent/WO2004045380A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/602—Glycosides, e.g. rutin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Birds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

This invention also provides a method to inhibit neovascularization in tissue by delivering to the cell or tissue an effective amount of a tannin, or a pharmaceutically acceptable salt, derivative, metabolite or pro-drug thereof. Also provided herein is a method for treating a disease associated with proliferation of endothelial cells and/or neovascularization by administering to a subject an effective amount of tannin, or a pharmaceutically acceptable salt, derivative or pro-drug thereof. Kits to treat patients are provided as well.
PCT/US2003/036708 2002-11-15 2003-11-17 Compositions containing an active fraction isolated from tannins and methods of use Ceased WO2004045380A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003291015A AU2003291015A1 (en) 2002-11-15 2003-11-17 Compositions containing an active fraction isolated from tannins and methods of use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42636302P 2002-11-15 2002-11-15
US60/426,363 2002-11-15

Publications (2)

Publication Number Publication Date
WO2004045380A2 WO2004045380A2 (en) 2004-06-03
WO2004045380A3 true WO2004045380A3 (en) 2004-07-15

Family

ID=32326339

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/036708 Ceased WO2004045380A2 (en) 2002-11-15 2003-11-17 Compositions containing an active fraction isolated from tannins and methods of use

Country Status (3)

Country Link
AU (1) AU2003291015A1 (en)
TW (1) TW200423954A (en)
WO (1) WO2004045380A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101583369B (en) 2006-11-15 2015-03-11 关节炎缓痛补充剂有限公司 Topical formulation and uses thereof
US8748177B2 (en) * 2008-09-30 2014-06-10 The Hospital For Sick Children Compositions for proliferation of cells and related methods
TWI407953B (en) * 2011-03-24 2013-09-11 Univ Kaohsiung Medical Pharmaceutical composition for modulating complement factor b (cfb) expression
RU2634253C1 (en) * 2016-12-22 2017-10-24 Федеральное государственное бюджетное учреждение "Российский онкологический научный центр имени Н.Н. Блохина" Министерства здравоохранения Российской Федерации (ФГБУ "РОНЦ им. Н.Н. Блохина" Минздрава России) Antiangiogenic drug
CN112870207B (en) * 2021-01-21 2022-08-02 广东盛普生命科技有限公司 Composition for preventing and/or treating organ fibrosis and application and preparation thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646136A (en) * 1994-01-04 1997-07-08 Duke University Methods of inhibiting angiogenesis and tumor growth, and treating ophthalmologic conditions with angiostatic and therapeutic steroids

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646136A (en) * 1994-01-04 1997-07-08 Duke University Methods of inhibiting angiogenesis and tumor growth, and treating ophthalmologic conditions with angiostatic and therapeutic steroids

Also Published As

Publication number Publication date
WO2004045380A2 (en) 2004-06-03
AU2003291015A8 (en) 2004-06-15
AU2003291015A1 (en) 2004-06-15
TW200423954A (en) 2004-11-16

Similar Documents

Publication Publication Date Title
WO2007149548A3 (en) Treatment of erectile dysfunction by stem cell therapy
WO2002047673A3 (en) Methods and compositions to treat conditions associated with neovascularization
WO2005091991A3 (en) Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of skin diseases or disorders
EP1933833B8 (en) Therapy for the treatment of overactive bladder
EA200600076A1 (en) COMPOSITIONS AND METHODS OF INCREASING THE ACTIVITY OF TELOMERASE
WO2008054544A3 (en) Method for delivery across the blood brain barrier
WO2007089584A3 (en) Compositions and their uses directed to huntingtin
WO2005013892A3 (en) Hydrolytically-resistant boron-containing therapeutics and methods of use
TW200833341A (en) 6-aminoimidazo[1,2-b]pyridazine analogs as rho kinase inhibitors for the treatment of rho kinase-mediated diseases and conditions
TW200609227A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
UA94097C2 (en) Pyridyl- and pyrimidinyl-substituted pyrrole-, thiophene- and furane-derivatives as kinase inhibitors
MX2010002392A (en) Improved brimonidine compositions for treating erythema.
WO2005117954A3 (en) Compositions and methods for treatment of neovascular diseases
MXPA06000302A (en) Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them.
MY143795A (en) Tetrahydropyridoindole derivatives
WO2005076979A3 (en) Diagnosis and therapeutics for cancer
NO20024646L (en) Combination therapies with vasculature-damaging activity
BR112012016128A2 (en) therapeutic agent (y-39983) for corneal endothelial dysfunction
WO2005060960A3 (en) Use of histamine to treat bone disease
WO2004045380A3 (en) Compositions containing an active fraction isolated from tannins and methods of use
WO2007077203A3 (en) Triterpenequinone and triterpenephenol derivatives and their application for the treatment of tumors and parasitic diseases
WO2004043346A3 (en) Compositions containing an active fraction isolated from lycium barbarum and methods of using the same
WO2004012677A3 (en) Methods and compositions to treat conditions associated with neovascularization
WO2005058341A3 (en) Compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
WO2004043345A3 (en) Extract of trapa natans and methods of using the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP